Pulmonary Hypertension in Interstitial Lung Disease (HYPID)
Recruitment status was Recruiting
HYPID study is an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided catheterization. The primary aim of the study is to identify prognostic factors.
Pulmonary Arterial Hypertension
Diffuse Interstitial Lung Disease
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Observational Study of Patients With Pre Capillary Pulmonary Hypertension|
- Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]Determine predictive factors of mortality
- Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]Determine cause of death
- Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]Determine survival and time to worsening
- Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]Analyse clinical, functional respiratory, hemodynamic features and changing characteristics of pulmonary hypertension
- Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]Document the efficacy of PH specific treatment
- Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]Evaluate the level of pulmonary arterial hypertension and compare the functional characteristics of patients with moderate or severe pulmonary hypertension
Biospecimen Retention: Samples With DNA
whole blood, serum and plasma
|Study Start Date:||July 2010|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
Pre capillary pulmonary hypertension (PH) may be present in patients with diffuse interstitial lung disease.
In this context, PH represents an important factor of morbidity and mortality for these patients.
One of the purposes of HYPID is to determine predictive factors of mortality within this cohort of patients.
In order to reach that aim,the study includes an evaluation based on exams conducted for the routine follow-up of patients. Each patient will be followed during 2 years at least.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01443598
|Contact: Vincent Cottin, MDfirstname.lastname@example.org|
|Contact: Stéphanie Polazziemail@example.com|
|Louis Pradel Hospital||Recruiting|
|Lyon (Bron), France, 69677|
|Contact: Vincent Cottin, MD 33-4-72-35-70-72 firstname.lastname@example.org|
|Contact: Sabrina Zeghmar 33-4-72-35-70-75 email@example.com|
|Principal Investigator: Vincent Cottin, MD|
|Principal Investigator:||Vincent Cottin, MD||Hospices Civils de Lyon / University Lyon I|